Uncategorized Archives - Page 40 of 142

MondayNov 28, 2022 9:06 am

European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment

U.S.-based drug innovator CNS Pharmaceuticals is continuing to advance its global human clinical trial for Berubicin, a potentially pivotal treatment for the incurable brain cancer glioblastoma CNS recently announced its Q3 financial results, including an update on the clinical development that noted the start of patient enrollment and dosing in France CNS is also advancing trial sites in the United States, Switzerland, Spain, and Italy, with 29 of 68 anticipated sites currently enrolling patients The company expects to provide an interim analysis of the trials in mid-2023 and primary completion in 2024, with ultimate resolution in 2025 The FDA has…

WednesdayNov 23, 2022 11:15 am

MetAlert Inc. (MLRT) Is ‘One to Watch’

MetAlert’s management team is highly experienced (several previous exits) in the tech, apparel, and wearable medical device industries, with significant management ownership (70%+) in MLRT The company operates in a large and growing global market in terms of potential revenue ($20-$50+ per month) and number of users (34+ million), with a potential impact on hundreds of millions The recent pandemic created an emphasis on health monitoring, especially for at-risk consumers/patients The recent pandemic negatively impacted the supply chain and shipping, creating a backlog of orders, but recent months’ activity suggests that the supply chain and shipping issues will be resolved…

WednesdayNov 23, 2022 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Announces New Chief Medical Officer

New Chief Medical Officer will play a major role in defining best paths to adoption, clinical strategies, and partnerships Dr. Fitzgerald serves as director of the Center for Cardiovascular Technology and of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School Dr. Fitzgerald brings impressive expertise in the clinical, research and industry sectors In a display of its commitment to offering innovative, high-quality products and services, cardiac tech company HeartBeam (NASDAQ: BEAT) has named a world-renowned interventional cardiologist with an impressive breadth of experience as its Chief Medical Officer (https://ibn.fm/pN1kf). Stanford cardiologist Peter J. Fitzgerald, MD, PhD, will help…

TuesdayNov 22, 2022 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Director of Communications and Investor Relations Presents at LD Micro Main Event

BiondVax summarizes collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen to discover and develop nanosized antibody (NanoAb) therapies that address underserved and growing markets, including COVID-19, psoriasis, asthma, psoriatic arthritis and wet macular degeneration. The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20% during the forecast period, resulting in a value of $35.42 billion by 2025 The psoriasis market is experiencing a higher-than-expected demand across all regions due to the increasing geriatric population and the growing prevalence of plaque…

TuesdayNov 22, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial

The National Brain Tumor Society anticipates that more than 13,000 Americans will receive a GBM diagnosis during 2022, accounting for 49.1% of all primary malignant brain tumors CNS announced the first patient in Europe has been enrolled and dosed in the global trial to evaluate Berubicin for the treatment of GBM Berubicin is a novel anthracycline and the first to appear to cross the blood-brain barrier The global GBM treatment market is expected to reach a value of $4.2 billion by 2028, driven by the increased approval granted by the FDA for novel GBM treatment therapies CNS Pharmaceuticals (NASDAQ: CNSP),…

MondayNov 21, 2022 12:00 pm

HeartBeam Inc. (NASDAQ: BEAT) Awarded Top Honors for Game-Changing Cardiovascular Tech Platform

BEAT named winner of the 2022 Cardiovascular Innovations (“CVI”) Innovation Summit and Shark Tank Competition Company’s presentation included an overview of its HeartBeam AIMI™ platform, which aids in more precise heart attack diagnosis HeartBeam is building an intellectual-property portfolio focused on enabling 12-lead electrocardiogram (“ECG”) diagnostics outside of a medical setting HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has been named winner of the annual Cardiovascular Innovations (“CVI”) 2022 Innovation Summit and Shark Tank Competition (https://ibn.fm/ftaNr). The annual conference focuses on innovative health solutions…

MondayNov 21, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Expands Executive Team of New Subsidiary in Strategic Move to Strengthen Marketing of Concussion, Neurological Therapies

Brain injuries affect all aspects of society, from recreational youth athletics to military trauma interventions Despite the commonality of brain concussion injuries — more than 5 million a year in the United States alone — no FDA-approved therapy exists Medical technology innovator Odyssey Health Inc. is working toward a commercialized product treatment solution to the unmet need of concussion injuries Odyssey’s product for treating brain concussion has recently completed a series of human and animal safety trials and is now being prepped for Phase II/III trials focused on proving efficacy The product administers neurosteroids across the blood-brain barrier to stop…

FridayNov 18, 2022 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Head of Technical R&D Presents Flagship NanoAbs Platform at Recent RAFT Conference

The presentation focused on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nanosized VHH-antibodies (NanoAbs) and highlighted the company’s NanoAbs as a platform for development of therapeutics addressing diseases with large unmet medical needs and attractive commercial opportunities BiondVax’s lead NanoAb candidate, an inhaled COVID-19 treatment, exhibits significant competitive advantages over currently available mAbs and oral COVID-19 therapies Development of additional NanoAbs, targeting psoriasis, asthma, psoriatic arthritis and wet macular degeneration is underway via a strategic collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Gottingen (“UMG”), both in Germany BiondVax Pharmaceuticals (NASDAQ: BVXV),…

WednesdayNov 16, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO Participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run Following European Clinical Trial Site Activations

CNS Pharmaceuticals CEO John Climaco participated in 5K run on November 5, to show support for brain tumor patients worldwide and help raise funds for research The company recently announced European clinical trial site activations for its potentially pivotal global trial evaluating Berubicin for the treatment of recurring glioblastoma multiforme The pivotal trial will study Berubicin’s results compared to the current study of care, Lomustine Global brain tumor treatment market was valued at $2,946 million in 2022 and is expected to grow to $5,904 million by 2032 Brain and other central nervous system cancers (“CNS”) represent 1.3% of all new…

MondayNov 14, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Focuses on Medical Devices Market with US Patent Application on Breath-Propelled Intranasal Delivery Device

Odyssey filed for US and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device that effectively deposits concentrated drug deep into the nasal cavity for the treatment of CNS injury disease or disorder The application follows the successful completion of the second Cohort of Odyssey’s Phase I MAD clinical trial, which saw the effective use of the device and a proven safety profile for the company’s concussion pharmaceutical treatment Michael Redmond, the company’s CEO, has expressed the company’s pleasure in the functionality of the device, citing how it provides a significant opportunity and advantage for the treatment of…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment

MetAlert Inc. (MLRT) Is ‘One to Watch’

HeartBeam Inc. (NASDAQ: BEAT) Announces New Chief Medical Officer

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Director of Communications and Investor Relations Presents at LD Micro Main Event

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial

HeartBeam Inc. (NASDAQ: BEAT) Awarded Top Honors for Game-Changing Cardiovascular Tech Platform

Odyssey Health, Inc. (ODYY) Expands Executive Team of New Subsidiary in Strategic Move to Strengthen Marketing of Concussion, Neurological Therapies

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Head of Technical R&D Presents Flagship NanoAbs Platform at Recent RAFT Conference

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO Participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run Following European Clinical Trial Site Activations

Odyssey Health, Inc. (ODYY) Focuses on Medical Devices Market with US Patent Application on Breath-Propelled Intranasal Delivery Device

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search